Cross-Seal IDE Trial: Prospective, Multicenter, Single-Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System

BACKGROUND: An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine th...

Full description

Saved in:
Bibliographic Details
Published inCirculation. Cardiovascular interventions Vol. 17; no. 6; p. e013842
Main Authors Krishnan, Prakash, Farhan, Serdar, Zidar, Frank, Krajcer, Zvonimir, Metzger, Christopher, Kapadia, Samir, Moore, Erin, Nazif, Tamim, Garland, Ty, Zhang, Ming, Khera, Sahil, Sharafuddin, Mel, Patel, Virendra I., Bacharach, John Michael, Coady, Paul, Schermerhorn, Marc L., Shames, Murray L., Rahimi, Saum, Panneton, Jean M., Elkins, Craig, Foteh, Mazin
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 01.06.2024
Subjects
Online AccessGet full text
ISSN1941-7640
1941-7632
1941-7632
DOI10.1161/CIRCINTERVENTIONS.123.013842

Cover

Loading…
Abstract BACKGROUND: An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths. METHODS: The Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure. RESULTS: A total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88). CONCLUSIONS: In selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03756558.
AbstractList An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths. The Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure. A total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88). In selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03756558.
An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths.BACKGROUNDAn increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths.The Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure.METHODSThe Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure.A total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88).RESULTSA total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88).In selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy.CONCLUSIONSIn selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy.URL: https://www.clinicaltrials.gov; Unique identifier: NCT03756558.REGISTRATIONURL: https://www.clinicaltrials.gov; Unique identifier: NCT03756558.
BACKGROUND: An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical access. However, vascular complications are a limitation for the management of these patients. This trial aimed to determine the effectiveness and safety of the Cross-Seal suture-mediated vascular closure device in obtaining hemostasis at the target limb access site following interventional procedures using 8F to 18F procedural sheaths. METHODS: The Cross-Seal IDE trial (Investigational Device Exemption) was a prospective, single-arm, multicenter study in subjects undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheaths. The primary efficacy end point was time to hemostasis at the target limb access site. The primary safety end point was freedom from major complications of the target limb access site within 30 days post procedure. RESULTS: A total of 147 subjects were enrolled between August 9, 2019, and March 12, 2020. Transcatheter aortic valve replacement was performed in 53.7% (79/147) and percutaneous endovascular abdominal/thoracic aortic aneurysm repair in 46.3% (68/147) of subjects. The mean sheath ID was 15.5±1.8 mm. The primary effectiveness end point of time to hemostasis was 0.4±1.4 minutes. An adjunctive intervention was required in 9.2% (13/142) of subjects, of which 2.1% (3/142) were surgical and 5.6% (8/142) endovascular. Technical success was achieved in 92.3% (131/142) of subjects. Freedom from major complications of the target limb access site was 94.3% (83/88). CONCLUSIONS: In selected patients undergoing percutaneous endovascular procedures utilizing 8F to 18F ID procedural sheath, Cross-Seal suture-mediated vascular closure device achieved favorable effectiveness and safety in the closure of the large-bore arteriotomy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03756558.
Author Kapadia, Samir
Nazif, Tamim
Coady, Paul
Shames, Murray L.
Schermerhorn, Marc L.
Moore, Erin
Metzger, Christopher
Rahimi, Saum
Elkins, Craig
Farhan, Serdar
Patel, Virendra I.
Sharafuddin, Mel
Krajcer, Zvonimir
Panneton, Jean M.
Khera, Sahil
Bacharach, John Michael
Krishnan, Prakash
Zidar, Frank
Garland, Ty
Zhang, Ming
Foteh, Mazin
Author_xml – sequence: 1
  givenname: Prakash
  orcidid: 0000-0003-2871-3689
  surname: Krishnan
  fullname: Krishnan, Prakash
  organization: Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (P.K., S.F., S. Khera)
– sequence: 2
  givenname: Serdar
  surname: Farhan
  fullname: Farhan, Serdar
  email: serdar.farhan@mountsinai.org
  organization: Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (P.K., S.F., S. Khera)
– sequence: 3
  givenname: Frank
  surname: Zidar
  fullname: Zidar, Frank
  email: frankjzidar@gmail.com
  organization: Department of Cardiology, Austin Heart, TX (F.Z.)
– sequence: 4
  givenname: Zvonimir
  surname: Krajcer
  fullname: Krajcer, Zvonimir
  email: zvonkomd@aol.com
  organization: Department of Vascular Surgery, Texas Heart Institute, Houston (Z.K.)
– sequence: 5
  givenname: Christopher
  surname: Metzger
  fullname: Metzger, Christopher
  email: david.metzger@balladhealth.org
  organization: Department of Cardiology, Wellmont Holston Valley Medical Center, Kingsport, TN (C.M.)
– sequence: 6
  givenname: Samir
  orcidid: 0000-0002-0026-3391
  surname: Kapadia
  fullname: Kapadia, Samir
  email: kapadis@ccf.org
  organization: Department of Cardiology, Cleveland Clinic, OH (S. Kapadia)
– sequence: 7
  givenname: Erin
  surname: Moore
  fullname: Moore, Erin
  email: vascularmd@gmail.com
  organization: Department of Vascular Surgery, River City Clinical Research, Jacksonville, FL (E.M.)
– sequence: 8
  givenname: Tamim
  surname: Nazif
  fullname: Nazif, Tamim
  email: tnazif@gmail.com
  organization: Department of Cardiology, Columbia University, New York, NY (T.N.)
– sequence: 9
  givenname: Ty
  surname: Garland
  fullname: Garland, Ty
  email: garland@vascularinstitute.com
  organization: Department of Vascular Surgery, Vascular Institute of the Rockies, Denver, CO (T.G.)
– sequence: 10
  givenname: Ming
  surname: Zhang
  fullname: Zhang, Ming
  email: ming.zhang@commonspirit.org
  organization: Department of Cardiology, Swedish Medical Center, Seattle, WA (M.Z.)
– sequence: 11
  givenname: Sahil
  orcidid: 0000-0001-9777-5934
  surname: Khera
  fullname: Khera, Sahil
  email: Sahil.Khera@mountsinai.org
  organization: Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (P.K., S.F., S. Khera)
– sequence: 12
  givenname: Mel
  surname: Sharafuddin
  fullname: Sharafuddin, Mel
  email: mel-sharafuddin@uiowa.edu
  organization: Department of Vascular Surgery, University of Iowa, Iowa City (M.S.)
– sequence: 13
  givenname: Virendra I.
  orcidid: 0000-0002-5578-0572
  surname: Patel
  fullname: Patel, Virendra I.
  email: vp2385@cumc.columbia.edu
  organization: New York Presbyterian, Columbia University, New York, NY (V.I.P.)
– sequence: 14
  givenname: John Michael
  surname: Bacharach
  fullname: Bacharach, John Michael
  organization: North Central Heart, Sioux Falls, SD (J.M.B.)
– sequence: 15
  givenname: Paul
  surname: Coady
  fullname: Coady, Paul
  email: coadypa@mlhs.org
  organization: Department of Cardiology, Lankenau Medical Center, Wynnewood, PA (P.C.)
– sequence: 16
  givenname: Marc L.
  orcidid: 0000-0002-4278-964X
  surname: Schermerhorn
  fullname: Schermerhorn, Marc L.
  email: mscherm@bidmc.harvard.edu
  organization: Department of Vascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA (M.L. Schermerhorn)
– sequence: 17
  givenname: Murray L.
  surname: Shames
  fullname: Shames, Murray L.
  email: mshames@health.usf.edu
  organization: Department of Vascular Surgery, University of South Florida, Tampa (M.L. Shames)
– sequence: 18
  givenname: Saum
  surname: Rahimi
  fullname: Rahimi, Saum
  email: rahimisa@rwjms.rutgers.edu
  organization: Department of Vascular Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (S.R.)
– sequence: 19
  givenname: Jean M.
  orcidid: 0000-0003-0632-309X
  surname: Panneton
  fullname: Panneton, Jean M.
  email: PannetJM@EVMS.EDU
  organization: Department of Vascular Surgery, Sentara Vascular Specialists, Norfolk, VA (J.P.)
– sequence: 20
  givenname: Craig
  surname: Elkins
  fullname: Elkins, Craig
  email: Craig.Elkins@integrishealth.org
  organization: Department of Vascular Surgery, INTEGRIS Baptist Medical Center, Oklahoma City, OK (C.E.)
– sequence: 21
  givenname: Mazin
  surname: Foteh
  fullname: Foteh, Mazin
  organization: Department of Vascular Surgery, Cardiothoracic and Vascular Surgeons, Austin, TX (M.F.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38708595$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1DAURi1URB_wF5AXLFg0g195IRat0gEitVPUDN1aTnLNBJxk8KPVLPnnuJpSIbFhZev63CP5-47RwTRPgNAbShaUZvRdVd9U9Wq9vLldrtb19apZUMYXhPJCsGfoiJaCJnnG2cHTXZBDdOzcd0LiOGMv0CEvclKkZXqEflV2di5pQBlcXyzx2g7KvMdf4nQLnR_u4BRfBeOHDiYP9hQ3w_TNQHJuR9z40O_wrLHfAP7L0wQfLCRX0A_KQ49vleuCURZXZnbxBV_AXfThZuc8jC_Rc62Mg1eP5wn6-nG5rj4nl9ef6ur8Muk4oyzpidaZTnWp01IwrpigZVsoQiFtU0KgZ6wTuiBa5FlaUkaJKnINbZa1mnPR8RP0du_d2vlnAOflOLgOjFETzMFJTlIqorXII_r6EQ3tCL3c2mFUdif_xBaBD3uge_i1Bf2EUCIfWpL_tCRjS3LfUlw_26_fzyaG6n6YcA9WbmJ4fvN_it8aOJvG
Cites_doi 10.1002/ccd.26686
10.1056/NEJMoa1816885
10.1016/j.jacc.2011.08.069
10.1016/j.jacc.2015.10.046
10.1056/NEJMoa1814052
10.1056/NEJMoa1008232
10.1161/JAHA.120.018042
10.1093/eurheartj/ehv417
10.1177/1526602820912224
10.1002/ccd.21711
10.1056/NEJMoa1400590
10.1016/j.jcin.2019.06.049
10.1056/NEJMoa1700456
10.3389/fcvm.2022.832242
10.4244/EIJ-D-20-01125
10.1056/NEJMoa1514616
10.1161/CIRCULATIONAHA.121.057856
10.1016/j.jaccas.2019.10.009
10.15420/icr.2018.36.1
10.1056/NEJMoa1103510
10.1016/S0140-6736(16)31135-7
10.1016/j.amjcard.2012.06.042
10.1016/j.amjcard.2016.11.009
10.1016/j.jvs.2017.05.122
10.1161/CIRCINTERVENTIONS.119.007258
10.1016/j.jcin.2020.09.052
10.1016/j.jvs.2013.10.101
10.1016/j.ijcard.2021.01.043
10.1016/j.carrev.2021.06.134
ContentType Journal Article
Copyright 2024 American Heart Association, Inc.
Copyright_xml – notice: 2024 American Heart Association, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/CIRCINTERVENTIONS.123.013842
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1941-7632
ExternalDocumentID 38708595
10_1161_CIRCINTERVENTIONS_123_013842
CIRCCVINT2023013842D
Genre research-article
Clinical Trial
Multicenter Study
Journal Article
GroupedDBID ---
.XZ
.Z2
0R~
18M
53G
5VS
6J9
AAAAV
AAHPQ
AAIQE
AAJCS
AARTV
AASCR
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACDDN
ACEWG
ACGFS
ACILI
ACWDW
ACWRI
ACXJB
ACXNZ
ADBBV
ADGGA
ADHPY
ADNKB
AEBDS
AEETU
AFBFQ
AFDTB
AFEXH
AFNMH
AFUWQ
AGINI
AHQNM
AHQVU
AHRYX
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BAWUL
BQLVK
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
EX3
F5P
FCALG
FL-
GNXGY
GQDEL
H13
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF7
KD2
KQ8
KQB
L-C
O9-
ODMTH
ODZKP
OHYEH
OK1
OPUJH
OUVQU
OVD
OVDNE
OXXIT
P6G
RAH
RIG
RLZ
S4S
TEORI
TR2
TSPGW
V2I
W2D
W3M
W8F
WOW
ZZMQN
AAYXX
ABPXF
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3212-d0ff6f5f9f59423a2419b8a01e5b500ed22c4f80f476591210a87feb66bf334c3
ISSN 1941-7640
1941-7632
IngestDate Fri Jul 11 12:43:13 EDT 2025
Mon Jul 21 06:02:00 EDT 2025
Thu Jul 03 08:29:58 EDT 2025
Wed Apr 16 02:25:37 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords sutures
blood pressure
hemostasis
vascular closure devices
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3212-d0ff6f5f9f59423a2419b8a01e5b500ed22c4f80f476591210a87feb66bf334c3
Notes Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/CIRCINTERVENTIONS.123.013842. For Sources of Funding and Disclosures, see page 530. Correspondence to: Prakash Krishnan, MD, Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P.B. 1030, New York, NY 10029. Email prakash.krishnan@mountsinai.org
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0026-3391
0000-0003-0632-309X
0000-0001-9777-5934
0000-0003-2871-3689
0000-0002-5578-0572
0000-0002-4278-964X
PMID 38708595
PQID 3051424187
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3051424187
pubmed_primary_38708595
crossref_primary_10_1161_CIRCINTERVENTIONS_123_013842
wolterskluwer_health_10_1161_CIRCINTERVENTIONS_123_013842
PublicationCentury 2000
PublicationDate 2024-June
2024-06-00
2024-Jun
20240601
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: 2024-June
PublicationDecade 2020
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Circulation. Cardiovascular interventions
PublicationTitleAlternate Circ Cardiovasc Interv
PublicationYear 2024
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References Barbash, Barbanti, Webb, Molina-Martin De Nicolas, Abramowitz, Latib, Nguyen, Deuschl, Segev, Sideris (R2) 2015; 36
Popma, Deeb, Yakubov, Mumtaz, Gada, O'Hair, Bajwa, Heiser, Merhi, Kleiman (R7) 2019; 380
Mack, Leon, Thourani, Makkar, Kodali, Russo, Kapadia, Malaisrie, Cohen, Pibarot (R6) 2019; 380
Reardon, Van Mieghem, Popma, Kleiman, Sondergaard, Mumtaz, Adams, Deeb, Maini, Gada (R18) 2017; 376
van Schaik, Yeung, Verhagen, de Bruin, van Sambeek, Balm, Zeebregts, van Herwaarden, Blankensteijn, participants (R19) 2017; 66
Toggweiler, Gurvitch, Leipsic, Wood, Willson, Binder, Cheung, Ye, Webb (R24) 2012; 59
Costa, Valvo, Picci, Criscione, Reddavid, Motta, Strazzieri, Deste, Giuffrida, Garretto (R26) 2021; 17
Patel, Sweeting, Powell, Greenhalgh, investigators (R20) 2016; 388
van Wiechen, Ligthart, Van Mieghem (R22) 2019; 14
Kodama, Yamamoto, Shimura, Kagase, Koyama, Tada, Takagi, Araki, Yamanaka, Shirai (R5) 2017; 90
Nelson, Kracjer, Kansal, Rao, Bianchi, Hashemi, Jones, Bacharach (R1) 2014; 59
Kahlert, Eggebrecht, Erbel, Sack (R25) 2008; 72
Nara, Watanabe, Kozuma, Kataoka, Nakashima, Hioki, Kawashima, Nagura, Shirai, Tada (R4) 2017; 119
Leon, Smith, Mack, Miller, Moses, Svensson, Tuzcu, Webb, Fontana, Makkar (R13) 2010; 363
Berti, Bedogni, Giordano, Petronio, Iadanza, Bartorelli, Reimers, Spaccarotella, Trani, Attisano (R21) 2020; 9
Masiero, D'Angelo, Fovino, Fabris, Cardaioli, Rodino, Benedetti, Boiago, Continisio, Montonati (R9) 2022; 9
Krajcer, Wood, Strickman, Bernardo, Metzger, Aziz, Bacharach, Nanjundappa, Campbell, Lee (R11) 2020; 27
van Wiechen, Tchetche, Ooms, Hokken, Kroon, Ziviello, Ghattas, Siddiqui, Laperche, Spitzer (R10) 2021; 14
Leon, Smith, Mack, Makkar, Svensson, Kodali, Thourani, Tuzcu, Miller, Herrmann (R15) 2016; 374
Van Mieghem, Tchetche, Chieffo, Dumonteil, Messika-Zeitoun, van der Boon, Vahdat, Buchanan, Marcheix, Himbert (R3) 2012; 110
Reifart, Liebetrau, Weferling, Dorr, Renker, Bhumimuang, Liakopoulos, Choi, Nef, Hamm (R23) 2021; 331
Adams, Popma, Reardon, Yakubov, Coselli, Deeb, Gleason, Buchbinder, Hermiller, Kleiman (R16) 2014; 370
Dumpies, Kitamura, Majunke, Hartung, Haag, Wilde, Desch, Sandri, Crusius, Noack (R8) 2022; 37
Moccetti, Brinkert, Seelos, Ockert, Bossard, Cuculi, Kobza, Toggweiler (R28) 2019; 12
Abdel-Wahab, Hartung, Dumpies, Obradovic, Wilde, Majunke, Boekstegers, Muller, Seyfarth, Vorpahl (R29) 2022; 145
Smith, Leon, Mack, Miller, Moses, Svensson, Tuzcu, Webb, Fontana, Makkar (R14) 2011; 364
Reynolds, Lei, Wang, Chinnakondepalli, Vilain, Magnuson, Galper, Meduri, Arnold, Baron (R17) 2016; 67
Liu, Sinning, Kao, Nickenig, Lin (R27) 2019; 1
Wood, Krajcer, Sathananthan, Strickman, Metzger, Fearon, Aziz, Satler, Waksman, Eng (R12) 2019; 12
e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_20_2
e_1_3_2_21_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
e_1_3_2_14_2
References_xml – volume: 110
  start-page: 1361
  year: 2012
  end-page: 1367
  ident: R3
  article-title: Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation.
  publication-title: Am J Cardiol
– volume: 1
  start-page: 549
  year: 2019
  end-page: 552
  ident: R27
  article-title: Acute femoral occlusion after adjunctive Angio-Seal usage in vascular closure following transcatheter aortic valve replacement.
  publication-title: JACC Case Rep
– volume: 14
  start-page: 17
  year: 2019
  end-page: 21
  ident: R22
  article-title: Large-bore vascular closure: new devices and techniques.
  publication-title: Interv Cardiol
– volume: 37
  start-page: 34
  year: 2022
  end-page: 40
  ident: R8
  article-title: Manta versus Perclose ProGlide vascular closure device after transcatheter aortic valve implantation: initial experience from a large European center.
  publication-title: Cardiovasc Revasc Med
– volume: 363
  start-page: 1597
  year: 2010
  end-page: 1607
  ident: R13
  article-title: Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
  publication-title: N Engl J Med
– volume: 12
  start-page: 1730
  year: 2019
  end-page: 1736
  ident: R28
  article-title: Insights from a multidisciplinary introduction of the MANTA vascular closure device.
  publication-title: JACC Cardiovasc Interv
– volume: 370
  start-page: 1790
  year: 2014
  end-page: 1798
  ident: R16
  article-title: Transcatheter aortic-valve replacement with a self-expanding prosthesis.
  publication-title: N Engl J Med
– volume: 331
  start-page: 183
  year: 2021
  end-page: 188
  ident: R23
  article-title: Single versus double use of a suture-based closure device for transfemoral aortic valve implantation.
  publication-title: Int J Cardiol
– volume: 364
  start-page: 2187
  year: 2011
  end-page: 2198
  ident: R14
  article-title: Transcatheter versus surgical aortic-valve replacement in high-risk patients.
  publication-title: N Engl J Med
– volume: 59
  start-page: 1181
  year: 2014
  end-page: 1193
  ident: R1
  article-title: A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial).
  publication-title: J Vasc Surg
– volume: 388
  start-page: 2366
  year: 2016
  end-page: 2374
  ident: R20
  article-title: Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial.
  publication-title: Lancet
– volume: 12
  start-page: e007258
  year: 2019
  ident: R12
  article-title: Pivotal clinical study to evaluate the safety and effectiveness of the MANTA percutaneous vascular closure device.
  publication-title: Circ Cardiovasc Interv
– volume: 119
  start-page: 611
  year: 2017
  end-page: 617
  ident: R4
  article-title: Incidence, predictors, and mid-term outcomes of percutaneous closure failure after transfemoral aortic valve implantation using an expandable sheath (from the Optimized Transcatheter Valvular Intervention [OCEAN-TAVI] registry).
  publication-title: Am J Cardiol
– volume: 66
  start-page: 1379
  year: 2017
  end-page: 1389
  ident: R19
  article-title: Long-term survival and secondary procedures after open or endovascular repair of abdominal aortic aneurysms.
  publication-title: J Vasc Surg
– volume: 27
  start-page: 414
  year: 2020
  end-page: 420
  ident: R11
  article-title: Pivotal clinical study to evaluate the safety and effectiveness of the MANTA vascular closure device during percutaneous EVAR and TEVAR procedures.
  publication-title: J Endovasc Ther
– volume: 374
  start-page: 1609
  year: 2016
  end-page: 1620
  ident: R15
  article-title: Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.
  publication-title: N Engl J Med
– volume: 17
  start-page: 728
  year: 2021
  end-page: 735
  ident: R26
  article-title: An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation.
  publication-title: EuroIntervention
– volume: 72
  start-page: 877
  year: 2008
  end-page: 884
  ident: R25
  article-title: A modified "preclosure" technique after percutaneous aortic valve replacement.
  publication-title: Catheter Cardiovasc Interv
– volume: 90
  start-page: E55
  year: 2017
  end-page: E62
  ident: R5
  article-title: Comparative data of single versus double proglide vascular preclose technique after percutaneous transfemoral transcatheter aortic valve implantation from the optimized catheter valvular intervention (OCEAN-TAVI) Japanese multicenter registry.
  publication-title: Catheter Cardiovasc Interv
– volume: 145
  start-page: 170
  year: 2022
  end-page: 183
  ident: R29
  article-title: Comparison of a pure plug-based versus a primary suture-based vascular closure device strategy for transfemoral transcatheter aortic valve replacement: The CHOICE-CLOSURE randomized clinical trial.
  publication-title: Circulation
– volume: 376
  start-page: 1321
  year: 2017
  end-page: 1331
  ident: R18
  article-title: Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.
  publication-title: N Engl J Med
– volume: 9
  start-page: e018042
  year: 2020
  ident: R21
  article-title: Efficacy and safety of ProGlide versus Prostar XL vascular closure devices in transcatheter aortic valve replacement: the RISPEVA registry.
  publication-title: J Am Heart Assoc
– volume: 36
  start-page: 3370
  year: 2015
  end-page: 3379
  ident: R2
  article-title: Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation.
  publication-title: Eur Heart J
– volume: 59
  start-page: 113
  year: 2012
  end-page: 118
  ident: R24
  article-title: Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure.
  publication-title: J Am Coll Cardiol
– volume: 14
  start-page: 149
  year: 2021
  end-page: 157
  ident: R10
  article-title: Suture- or plug-based large-bore arteriotomy closure: a pilot randomized controlled trial.
  publication-title: JACC Cardiovasc Interv
– volume: 9
  start-page: 832242
  year: 2022
  ident: R9
  article-title: Real-world experience with a large bore vascular closure device during TAVI procedure: features and predictors of access-site vascular complications.
  publication-title: Front Cardiovasc Med
– volume: 380
  start-page: 1695
  year: 2019
  end-page: 1705
  ident: R6
  article-title: Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.
  publication-title: N Engl J Med
– volume: 380
  start-page: 1706
  year: 2019
  end-page: 1715
  ident: R7
  article-title: Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients.
  publication-title: N Engl J Med
– volume: 67
  start-page: 29
  year: 2016
  end-page: 38
  ident: R17
  article-title: Cost-effectiveness of transcatheter aortic valve replacement with a self-expanding prosthesis versus surgical aortic valve replacement.
  publication-title: J Am Coll Cardiol
– ident: e_1_3_2_6_2
  doi: 10.1002/ccd.26686
– ident: e_1_3_2_8_2
  doi: 10.1056/NEJMoa1816885
– ident: e_1_3_2_25_2
  doi: 10.1016/j.jacc.2011.08.069
– ident: e_1_3_2_18_2
  doi: 10.1016/j.jacc.2015.10.046
– ident: e_1_3_2_7_2
  doi: 10.1056/NEJMoa1814052
– ident: e_1_3_2_14_2
  doi: 10.1056/NEJMoa1008232
– ident: e_1_3_2_22_2
  doi: 10.1161/JAHA.120.018042
– ident: e_1_3_2_3_2
  doi: 10.1093/eurheartj/ehv417
– ident: e_1_3_2_12_2
  doi: 10.1177/1526602820912224
– ident: e_1_3_2_26_2
  doi: 10.1002/ccd.21711
– ident: e_1_3_2_17_2
  doi: 10.1056/NEJMoa1400590
– ident: e_1_3_2_29_2
  doi: 10.1016/j.jcin.2019.06.049
– ident: e_1_3_2_19_2
  doi: 10.1056/NEJMoa1700456
– ident: e_1_3_2_10_2
  doi: 10.3389/fcvm.2022.832242
– ident: e_1_3_2_27_2
  doi: 10.4244/EIJ-D-20-01125
– ident: e_1_3_2_16_2
  doi: 10.1056/NEJMoa1514616
– ident: e_1_3_2_30_2
  doi: 10.1161/CIRCULATIONAHA.121.057856
– ident: e_1_3_2_28_2
  doi: 10.1016/j.jaccas.2019.10.009
– ident: e_1_3_2_23_2
  doi: 10.15420/icr.2018.36.1
– ident: e_1_3_2_15_2
  doi: 10.1056/NEJMoa1103510
– ident: e_1_3_2_21_2
  doi: 10.1016/S0140-6736(16)31135-7
– ident: e_1_3_2_4_2
  doi: 10.1016/j.amjcard.2012.06.042
– ident: e_1_3_2_5_2
  doi: 10.1016/j.amjcard.2016.11.009
– ident: e_1_3_2_20_2
  doi: 10.1016/j.jvs.2017.05.122
– ident: e_1_3_2_13_2
  doi: 10.1161/CIRCINTERVENTIONS.119.007258
– ident: e_1_3_2_11_2
  doi: 10.1016/j.jcin.2020.09.052
– ident: e_1_3_2_2_2
  doi: 10.1016/j.jvs.2013.10.101
– ident: e_1_3_2_24_2
  doi: 10.1016/j.ijcard.2021.01.043
– ident: e_1_3_2_9_2
  doi: 10.1016/j.carrev.2021.06.134
SSID ssj0063262
Score 2.3859024
Snippet BACKGROUND: An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than...
An increasing number of interventional procedures require large-sheath technology (>12F) with a favorable outcome with endovascular rather than open surgical...
SourceID proquest
pubmed
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage e013842
SubjectTerms Aged
Aged, 80 and over
Aortic Aneurysm, Abdominal - diagnostic imaging
Aortic Aneurysm, Abdominal - surgery
Aortic Aneurysm, Thoracic - diagnostic imaging
Aortic Aneurysm, Thoracic - surgery
Blood Vessel Prosthesis Implantation - adverse effects
Blood Vessel Prosthesis Implantation - instrumentation
Catheterization, Peripheral - adverse effects
Catheterization, Peripheral - instrumentation
Endovascular Procedures - adverse effects
Endovascular Procedures - instrumentation
Equipment Design
Female
Hemorrhage - etiology
Hemorrhage - prevention & control
Hemostatic Techniques - adverse effects
Hemostatic Techniques - instrumentation
Humans
Male
Middle Aged
Prospective Studies
Punctures
Risk Factors
Suture Techniques - adverse effects
Suture Techniques - instrumentation
Time Factors
Transcatheter Aortic Valve Replacement - adverse effects
Transcatheter Aortic Valve Replacement - instrumentation
Treatment Outcome
Vascular Closure Devices
Title Cross-Seal IDE Trial: Prospective, Multicenter, Single-Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1161/CIRCINTERVENTIONS.123.013842
https://www.ncbi.nlm.nih.gov/pubmed/38708595
https://www.proquest.com/docview/3051424187
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfKkBAIIRAwypeMtDeWkuY7vKG01cpYKayrpr1EjmOLstKgtAXBG_8sfwd3dtIkdEIDXqIqaS5u7xff-Xz3O0L2hGQWC7uWIXzbMRzH943EhhfPd3nq2mliSoaFwkcj7-DEeX3qnrZaP2tZS-tV0uHfL6wr-RetwjnQK1bJ_oVmN0LhBHwG_cIRNAzHS-k4QhNnHCM38LDXfz7BR-ISf5xnZQWlCngqig0k39RNtsBazYUBKlZZhN_KNIGatGPFNGIcqT4e4JJOy3zVaJ5hSBFzjWbI4al4oOsObjTLedERrIPZJI1k11p-ZbWHhC3uiybJ45yds-UmQD1g-YciPivylG3SiM9mqU4LVx3nK0HsI9e_8OwLzFSfZnk9pGE5VeqVDmlcQE2hQhqzOeYNaculp-vQ6RowQzbnc7-G2_rkLHBXVnN5bRsODw1HNHwfKSriaX-kqrg7YNg71W1Nvu7R23jcG8RvhqPD5kXlHqCsaArSsEG9FtG7Qq5asJzBThuH7za7XTB-z7pG9opxvPjTKJru09aa6Aa5-TXDNIvluaqyqPlKk9vkVrHIoa80Yu-QlljcJT8qfFFAK1VofUlrWN2nNaTu0wqnVOGUZpICTmlNzm84pSVOaYFTqnFKNU7vkZNBfxIdGEUDEIPb4FIZqSmlJ10ZSjcEt5-BtxkmATO7wk1c0xSpZXFHBqZ0fM8NkQqPBb4Uiecl0rYdbt8nO4tsIR4QGgj4UsK5H6TMCTybge2RPBDg8ZrctYI2ccv_Nf6seV5itT72uvGWPmLQR6z10SbPSiXEMDHjbhtbiGy9jG3sLAAjDvw22dXa2Ui2wUoisWCbhA11xbr4-VJPfvgf9z4i16v37jHZWeVr8QSc61XyVCHzF4Cp0O4
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-Seal+IDE+Trial%3A+Prospective%2C+Multicenter%2C+Single-Arm+Study+of+the+Cross-Seal+Suture-Mediated+Vascular+Closure+Device+System&rft.jtitle=Circulation.+Cardiovascular+interventions&rft.au=Krishnan%2C+Prakash&rft.au=Farhan%2C+Serdar&rft.au=Zidar%2C+Frank&rft.au=Krajcer%2C+Zvonimir&rft.date=2024-06-01&rft.pub=Lippincott+Williams+%26+Wilkins&rft.eissn=1941-7632&rft.volume=17&rft.issue=6&rft.spage=e013842&rft_id=info:doi/10.1161%2FCIRCINTERVENTIONS.123.013842&rft.externalDBID=NO_PDF_LINK&rft.externalDocID=CIRCCVINT2023013842D
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7640&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7640&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7640&client=summon